Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

Next Previous
Trial Profile

A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Drisapersen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms DEMAND III
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 11 Mar 2022 According to a PTC Therapeutics media release, results evaluating associations between Deflazacort vs Prednisone/prednisolone and disease progression markers in subgroup of patients with Duchenne Muscular Dystrophy (NCT01826487, NCT01865084, NCT00592553, NCT01254019) will be presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2022. Abstract is available on the MDA Conference website.
    • 24 Nov 2015 According to a BioMarin Pharmaceutical media release, The Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. FDA has reviewed the NDA for drisapersen for the treatment of duchenne muscular dystrophy amenable to exon 51 skipping.
    • 20 Nov 2015 According to a BioMarin Pharmaceutical media release, the Prescription Drug User Fee Act (PDUFA) action date for completion of FDA review of the Kyndrisa NDA is December 27, 2015.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top